308) ified sensitivity of radiomic features to tumor boundaries. |
309) overcame insufficient immunity at distant tumor caused by PTT alone and relieved imm |
310) ercoming insufficient immunity at distant tumor caused by PTT alone. |
311) sessed and optimized in order to maximize tumor-absorbed dose while keeping normal o |
312) Such imaging may be used to estimate tumor-absorbed dose. |
313) ws the research results on organoids from tumor drug screening. |
314) ir applications in cancer therapy include tumor-targeting drug delivery and controll |
315) and anti-PD-1 cotreatment may enhance antitumor effects consistent with an increase |
316) ide the first line of defense against the tumor-promoting effects of oxidative stres |
317) D20 CAR T cells demonstrate improved anti-tumor efficacy in response to dual antigen |
318) In this study, we evaluated the anti-tumor efficacy of DARA conjugated to the m |
319) free method to examine specimens of both tumor entities intraoperatively, as well a |
320) rest classification distinguished the two tumor entities with a balanced accuracy of |
321) Both, glioblastoma and tumor-associated epilepsy are closely link |
322) ressing glutamate receptors in glioma and tumor-related epilepsy will be highlighted |
323) A merit in the early stages of tumor formation, autophagy appears to be s |
324) In the early stages of tumor formation, autophagy appears to be s |
325) However, the inter-patient and intra-tumor heterogeneity has not been addressed |
326) Genetic investigation of tumor heterogeneity and clonal evolution i |
327) rences across patients, and the impact of tumor hypoxia on response to RPT. |
328) mic therapy (PDT) of cancer is limited by tumor hypoxia. |
329) Here, we examined how CD8+ tumor infiltrating lymphocytes (TILs) resp |
330) gand 1 (PD-L1) and increased intensity of tumor infiltrating lymphocytes. |
331) NAseq demonstrated that obesity decreased tumor-infiltrating lymphocyte frequencies, |
332) nform developmental relationships between tumor-infiltrating lymphocyte subpopulatio |
333) eoperative studies (physical examination, tumor markers, and imaging) to determine t |
334) onclusive testicular tumors with negative tumor markers, frozen section examination |
335) important regulators of tumorigenesis and tumor metastasis. |
336) enesis of several diseases, especially in tumor metastasis. |
337) reference pathology, genetic testing for tumor predisposition syndromes in selected |
338) some SCSTs may develop in the context of tumor predisposition syndromes, for exampl |
339) een identified as a common contributor to tumor progression, including invasion and |
340) lyamine metabolism can be used to disrupt tumor progression, modulate tumor microenv |
|